September 30, 2026 · Phase 3 readout
RYTM Phase 3 readout: a neutral outcome, -0.5%
On September 30, 2026, Setmelanotide — RHYTHM PHARMACEUTICALS, INC. (Genetic Obesity) reached its Phase 3 readout. The result was a neutral outcome, and the stock moved -0.5% in the window around the event. It had already run -7.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$95.71
1d before
$95.21
Event day
$93.41
1d after
$92.45
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+3.2% expected); the stock actually moved -0.5%. Model confidence at the time: 82%.
See the full scored track recordPre-catalyst setup
-7.0%
30-day run-up
2776%
30-day volatility
1.3×
volume spike
